Accelerating proof of concept for small molecule drugs using solid-state chemistry

Journal of Pharmaceutical Sciences

Volumn 99, Issue 9, 2010, Pages 3665-3675

  Byrn, Stephen R ^a   Zografi, George ^b   Chen, Xiaoming ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c OSI Pharmaceuticals Inc   (United States)

Author keywords

Amorphous; Biomarker; Co crystals; Polymorphs; Proof of concept; Quality by design; Salts; Solid state chemistry; Solubility; Stability; Translational science

Indexed keywords

CLOPIDOGREL; ERLOTINIB; MERCAPTOPURINE; MOMETASONE FUROATE; PEGINTERFERON ALPHA; RIBAVIRIN; RITONAVIR;

ARTICLE; COST EFFECTIVENESS ANALYSIS; CRYSTALLIZATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG FORMULATION; DRUG INDUSTRY; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HEPATITIS C; HUMAN; LUNG CANCER; PHARMACOGENETICS; SOLID STATE;

EID: 77956374119     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22215     Document Type: Article

References (41)

1. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid-state chemistry of drugs. West Lafayette, IN: SSCI, Inc.
2. Kerns EH, Di L. 2003. Pharmaceutical profiling in drug discovery. Drug Discov Today 7:316-323.
3. Thompson MD, Authelin JR. 1999. Chemical development of the drug substance solid form. In: Gadamasetti KG, editor. Process chemistry in the pharmaceutical industry. New York: Marcel Dekker. pp 371-388.
4. Myerson AS, Jacovs J, Jacovs J. 1993. Handbook of industrial crystallization. Massachusetts: Butterworth-Heinemann.
5. Gardner CR, Walsh CT, Almarsson OA. 2004. Drugs as materials: Valuing physical form in drug discovery. Nat Rev Drug Discov 3:926-934.
6. Henck JO, Bryn SR. 2007. Designing a molecular delivery system within a preclinical timeframe. Drug Discov Today 12:189-199. (Pubitemid 46316891)
7. Brouwers J, Brewster ME, Augustijns P. 2009. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability. J Pharm Sci 98:2549-2572.
8. Singhal D, Curatolo W. 2004. Drug polymorphism and dosage form design: A practical perspective. Adv Drug Deliv Rev 56:335-347.
9. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guideline Q8 and Q9.
10. Bittain HG, editor. 2009. Polymorphism in pharmaceutical solids, 2nd edition. New York: Informa Healthcare.
11. Hilfiker R, editor. Polymorphism in the pharmaceutical industry. Weinheim: Wiley-VCH.
12. Rodriguez-Spong B, Price CP, Jayasankar A, Matzger AJ, Rodriguez-Hornedo N. 2004. General principles of pharmaceutical solid polymorphism: A supramolecular perspective. Adv Drug Deliv Rev 56:241-274. (Pubitemid 38201425)
13. Law D, Schmitt EA, Marsh KC, Everitt EA, Wang W, Fort JJ, Krill SL, Qiu Y. 2004. Ritonavir-PEG 8000 amorphous solid dispersions: In vitro and in vivo evaluations. J Pharm Sci 93:563-570.
14. Jarvis B, Simpson K. 2000. Clopidogrel: A review of its use in the prevention of atherothrombosis. Drugs 60:347-377.
15. Agrawal H, Kaul N, Paradkar AR, Mahadik KR. 2003. Stability indicating HPLC determination of clopidogrel bisulphate as bulk drug and in pharmaceutical dosage form. Talanta 61:581-589.
16. Gomez Y, Adams E, Hoogmartens J. 2004. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm Biomed Anal 34:341-348. (Pubitemid 38167764)
17. Yuen P, Eckhart C, Etlinger T, Levine N. 2000. Mometasone furoate monohydrate, process for making same and pharmaceutical compositions. United States Patent 6127353.
18. Chen X, Carillo M, Haltiwanger RC, Bradley P. 2005. Solid state characterization of mometasone furoate anhydrous and monohydrate forms. J Pharm Sci 94:2496-2509.
19. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. 2010. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9:203-214.
20. Goulart BHL, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. 2007. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 13:6719-6726.
21. Lennard L, Gibson BE, Nicole T, Lilleyman JS. 1993. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 69:577-579. (Pubitemid 23355853)
22. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy D, Okamoto H, Pawlotsky J, Penin F, Sablon E, Shin-I T, Stuyver L, Thiel H, Viazov S, Weiner A, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973.
23. Amann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, Carbone DP. 2010. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 5. 169-178.
24. Webb CP, Pass HI. 2004. Translation research: From accurate diagnosis to appropriate treatment. J Trans Med 2:1-22.
25. Dennen P, Parikh CR. 2007. Biomarkers of acute kidney injury: Can we replace serum creatinine? Clin Nephrol 68:269-278.
26. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. 2004. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791.
27. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. 2008. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 117:743-753. (Pubitemid 351640675)
28. Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, Ette E, Gallo P, Hirsch G, Mehta C, Patel N, Sabir S, Springs S, Stanski D, Evers MR, Fleming E, Singh N, Tramontin T, Golub H. 2009. The future of drug development: Advancing clinical trial design. Nat Rev Drug Discov Today 8:940-957.
29. Anonymous. 2007. Pharma 2020: The vision. Which path will you take? PricewaterhouseCoopers online publication. www.pwc.com/pharma.
30. Elias T, Gordian M, Singh N, Zemmel R. 2006. Why products fail in Phase III. In Vivo 4:1-8.
31. Miller JM, Collman BM, Greene LR. 2005. Identifying the stable polymorph early in the drug discovery - Development process. Pharm Dev Tech 10:291-297.
32. Burger A, Griesser UJ. 1989. The polymorphic drug substances of the European Pharmacopeia. Part 4. Identification and characterization of 11 crystal forms of succinylsulfathiazole. Sci Pharm 57:293-305.
33. Tong WQ, Whitesell G. 1998. In situ salt screening - A useful technique for discovery support and preformulation studies. Pharm Dev Tech 3:215-223.
34. Miroshnyk I, Mirza S, Sandler N. 2009. Pharmaceutical cocrystals - An opportunity for drug product enhancement. Expert Opin Drug Deliv 6:333-341.
35. Trask AV, Motherwell WDS, Jones W. 2005. Pharmaceutical co-crystallization: Engineering a remedy for caffeine hydration. Cryst Growth Des 5:1013-1021.
36. Trask AV, Jones W. 2005. Crystal engineering of organic cocrystals by the solid-state grinding approach. Topics Curr Chem 254:41-47.
37. Crowley KJ, Zografi G. 2002. Cryogenic grinding of indomethacin polymorphs and solvates: Assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci 91:492-507. (Pubitemid 34139812)
38. Brouwers J, Brewster ME, Augustinjns P. 2009. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability? J Pharm Sci 98:2549-2572.
39. Uekama K, Ikegami K, Wang Z, Horiuchi Y, Hirayama F. 1992. Inhibitory effect of 2-hydroxypropyl-beta-cyclodextrin on crystal-growth of nifedipine during storage: Superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30. J Pharm Pharmacol 44:73-78.
40. Vandecruys R, Peeters J, Verreck G, Brewster ME. 2007. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int J Pharm 342:168-175. (Pubitemid 47259339)
41. Pisano GP. 1996. The development factory: Unlocking the potential of process innovation. Boston: Harvard Business School Press.